Acumen Pharma Expects Topline Results From ALTITUDE-AD In Late 2026; Targets Submission Of IND Filing With Respect To Lead Clinical Candidate In EBD Program In Mid-2027

Benzinga Newsdesk www.benzinga.com Neutral 65.3%

Neg 0% Neu 65.3% Pos 0%

Comments

No comments yet. Be the first!